Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations.
COPD
Exacerbations
Physical activity
Randomized controlled trial
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
23
09
2019
revised:
08
01
2020
accepted:
09
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
17
9
2020
Statut:
ppublish
Résumé
Technology-based physical activity (PA) interventions have been shown to improve daily step counts and health-related quality of life, but their effect on long-term clinical outcomes like acute exacerbations (AEs) is unknown in persons with COPD. U.S. Veterans with stable COPD were randomized (1:1) to either pedometer alone (control) or pedometer plus a website with feedback, goal-setting, disease education, and a community forum (intervention) for 3 months. AEs were assessed every 3 months over a follow-up period of approximately 15 months. Pedometer-assessed daily step counts, health-related quality-of-life (HRQL), and self-efficacy were assessed at baseline, end-of-intervention at 3 months, and during follow-up approximately 6 and 12 months after enrollment. Zero-inflated Poisson models assessed the effect of the intervention on risk for AEs, compared to controls. Generalized linear mixed-effects models for repeated measures examined between-group and within-group changes in daily step count, HRQL, and self-efficacy. There were no significant differences in age, FEV A 3-month internet-mediated, pedometer-based PA intervention was associated with reduced risk for AEs of COPD over 12-15 months of follow-up. ClinicalTrials.gov identifier: NCT01772082.
Sections du résumé
BACKGROUND
Technology-based physical activity (PA) interventions have been shown to improve daily step counts and health-related quality of life, but their effect on long-term clinical outcomes like acute exacerbations (AEs) is unknown in persons with COPD.
METHODS
U.S. Veterans with stable COPD were randomized (1:1) to either pedometer alone (control) or pedometer plus a website with feedback, goal-setting, disease education, and a community forum (intervention) for 3 months. AEs were assessed every 3 months over a follow-up period of approximately 15 months. Pedometer-assessed daily step counts, health-related quality-of-life (HRQL), and self-efficacy were assessed at baseline, end-of-intervention at 3 months, and during follow-up approximately 6 and 12 months after enrollment. Zero-inflated Poisson models assessed the effect of the intervention on risk for AEs, compared to controls. Generalized linear mixed-effects models for repeated measures examined between-group and within-group changes in daily step count, HRQL, and self-efficacy.
RESULTS
There were no significant differences in age, FEV
CONCLUSIONS
A 3-month internet-mediated, pedometer-based PA intervention was associated with reduced risk for AEs of COPD over 12-15 months of follow-up. ClinicalTrials.gov identifier: NCT01772082.
Identifiants
pubmed: 32056676
pii: S0954-6111(20)30018-4
doi: 10.1016/j.rmed.2020.105878
pmc: PMC7269114
mid: NIHMS1591103
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT01772082']
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
105878Subventions
Organisme : RRD VA
ID : IK2 RX002165
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Moy reports receiving an honorarium for consulting from AstraZeneca, outside the submitted work. The remaining authors have no relevant conflicts to disclose.
Références
Respir Med. 2015 Jan;109(1):112-21
pubmed: 25499548
Physiotherapy. 2019 Mar;105(1):90-97
pubmed: 30316548
Int J Chron Obstruct Pulmon Dis. 2015 Jun 08;10:1061-73
pubmed: 26089656
PLoS One. 2013 Apr 04;8(4):e60400
pubmed: 23593211
Ann Am Thorac Soc. 2018 Apr;15(4):470-478
pubmed: 29283670
Ann Am Thorac Soc. 2015 Mar;12(3):349-56
pubmed: 25568929
Chest. 2014 Mar 1;145(3):542-550
pubmed: 24091482
Chest. 2015 Jul;148(1):128-137
pubmed: 25811395
Eur Respir J. 2016 Oct;48(4):1019-1029
pubmed: 27587557
BMC Pulm Med. 2014 Feb 03;14:12
pubmed: 24491137
Respir Med. 2018 Aug;141:1-6
pubmed: 30053953
BMC Pulm Med. 2015 Nov 04;15:136
pubmed: 26530543
Respir Med. 2012 Jul;106(7):962-9
pubmed: 22521225
J Cardiopulm Rehabil Prev. 2018 Sep;38(5):333-341
pubmed: 29757825
Ann Am Thorac Soc. 2014 Jun;11(5):695-705
pubmed: 24713094
Eur Respir J. 2018 Oct 18;52(4):
pubmed: 30166322
Int J Chron Obstruct Pulmon Dis. 2009;4:301-13
pubmed: 19750190
Thorax. 2013 Oct;68(10):962-3
pubmed: 23604460
ERJ Open Res. 2016 Mar 17;2(1):
pubmed: 27730174
J Med Internet Res. 2016 Aug 08;18(8):e215
pubmed: 27502583
Respir Med. 2017 Sep;130:102-110
pubmed: 29206627
Heart Lung. 2007 May-Jun;36(3):205-16
pubmed: 17509427
Chron Respir Dis. 2013;10(4):207-13
pubmed: 24177682
Thorax. 2017 May;72(5):415-423
pubmed: 28137918
Chest. 2011 Aug;140(2):331-342
pubmed: 21273294
Eur Respir J. 2015 Feb;45(2):347-54
pubmed: 25261324
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
pubmed: 1595997
JAMA. 2014 Jan 8;311(2):183-92
pubmed: 24399557
J Behav Med. 2019 Dec;42(6):1082-1090
pubmed: 30980223
J Med Internet Res. 2015 Jul 24;17(7):e184
pubmed: 26209025
Respir Med. 2014 Apr;108(4):628-37
pubmed: 24451438
Natl Vital Stat Rep. 2018 Jul;67(5):1-76
pubmed: 30248015